AstraZeneca's global biologics research and development division MedImmune will acquire Spirogen, a biotech firm focused on antibody-drug conjugate technology for use in oncology. Spirogen's complete shares will be purchased by MedImmune ...
Tags: biologics research, AstraZeneca
Swiss drugmaker F. Hoffmann-La Roche has announced that the EU’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending authorization of Kadcyla as a single agent for the treatment of adult ...
Tags: Breast Cancer Drug
Ventana Medical Systems,a member of the Roche Group, and pharmaceutical company Boehringer Ingelheim (BI) have entered into a collaboration agreement for the development of companion diagnostic tests for BI oncology programs. Companion ...
India-based Biocon is likely to launch the Swiss drugmaker Roche's Herceptin (trastuzumab) biosimilar version by the end of 31 March 2014, following the latter's decision to give up a patent fight over the breast cancer drug in the country. ...
India has partly suspended patents granted to Roche Holding for its breast cancer drug Herceptin, over issues that the patents had not been filed in accordance with the laid down process. An article published in Swiss newspaper Schweiz am ...
Tags: Cancer Drug Patent
The Intellectual Property Appellate Board (IPAB) in India has cancelled the patent for GlaxoSmithKline's (GSK) anti-cancer drug Tykerb in its salt form over failure in demonstrating significant improvement in the efficacy. Fresenius ...
Tags: Anti-Cancer Drug
German pharma and chemical firm Bayer has reported a net profit of €841m for the second quarter of 2013, with an increase of 74.8% compared to €481m during the comparable period earlier year. The increase in profit is primarily ...
Tags: chemical firm, Bayer
The UK National Institute for Health and Care Excellence (NICE) has rejected Pfizer’s new chronic myeloid leukaemia (CML) drug, Bosulif (bosutinib). NICE chief executive Sir Andrew Dillon said there is evidence to suggest that ...
Tags: Cancer Drug, Medicine
US-based Johnson & Johnson has agreed to buy Aragon Pharmaceuticals, a discovery and development company focused on drugs to treat hormonally-driven cancers, for nearly $1bn. As per the acquisition agreeement, an upfront cash payment of ...
Tags: Johnson&Johnson, Medicine
Oncology-focused company Curis has announced the approval of Erivedge (vismodegib) in Australia for the treatment of metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma in adult patients who are not suitable for ...
Tags: Curis, Erivedge Anti-Cancer Drug
If you've ever had trouble affording your medications and wanted to call your doctor on it, here's some encouraging news: Doctors aren't pleased about the prices either. Denouncing "profiteering" by pharmaceutical companies, more than 100 ...
Genalice, a US-based software solutions developer for DNA analysis, will soon release the beta version of Genalice Map. The solution Genalice Map can process raw DNA data, which is produced by the sequencers, and stores the data in a ...
Tags: Genalice, Raw DNA Sequence Data
Pfizer has received breakthrough therapy designation from the United States Food and Drug Administration (FDA) for its investigational compound Palbociclib, a potential treatment for patients with breast cancer. The breakthrough therapy ...
Tags: Cancer Drug, Pfizer, Therapy Designation
Aeterna Zentaris has signed a co-development and profit sharing agreement with Ergomed Clinical Research for AEZS-108 in endometrial cancer. Ergomed has been selected as the contract clinical development organization to conduct the Phase ...
The Indian Supreme Court has rejected Novartis' patent application for its anti-cancer drug Glivec (imatinib mesylate) saying that “application for patent on the beta-crystalline salt does not meet any standard of novelty or ...
Tags: Indian Apex, Novartis'Patent Plea, Glivec